Viridian Therapeutics
VRDN
122 hedge funds and large institutions have $1.21B invested in Viridian Therapeutics in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 52 increasing their positions, 29 reducing their positions, and 12 closing their positions.
150% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 12
79% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 29
55% more capital invested
Capital invested by funds: $778M → $1.21B (+$427M)
16% more funds holding
Funds holding: 105 → 122 (+17)
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
2.77% more ownership
Funds ownership: 99.68% → 102.45% (+2.8%)
3% less call options, than puts
Call options by funds: $3.47M | Put options by funds: $3.58M
Top Buyers
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$21.3M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$19M |
| 3 |
BlackRock
New York
|
+$18M |
| 4 |
State Street
Boston,
Massachusetts
|
+$15.8M |
| 5 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$13.6M |
Top Sellers
| 1 |
CC
Commodore Capital
New York
|
-$15.6M |
| 2 |
Barclays
London,
United Kingdom
|
-$12.8M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$11.6M |
| 4 |
EP
Eversept Partners
New York
|
-$9.81M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$8.52M |
VRDN Hedge Fund Activity: Q4 2022 in Review
122 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2022, worth a combined $1.21B — up 55% from $778M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new VRDN positions and 12 closed out — a net gain of 18 holders — while 52 added to existing stakes and 29 trimmed.
The largest buyer was AllianceBernstein, opening a new position worth an estimated $21.3M. The largest seller was Commodore Capital, cutting an estimated $15.6M.
- 122 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2022, up from 105 in Q3 2022.
- Funds reported $1.21B of Viridian Therapeutics stock for Q4 2022, up 55% quarter-over-quarter.
- 30 funds opened new Viridian Therapeutics positions in Q4 2022 and 12 closed out, a net change of +18 holders.
- The largest Viridian Therapeutics buyer in Q4 2022 was AllianceBernstein, an estimated $21.3M added.
- The largest Viridian Therapeutics seller in Q4 2022 was Commodore Capital, an estimated $15.6M sold.
Based on aggregated 13F filings for Q4 2022.